companies

EarlySight

Founded 2019
Employees 10+
Primary contact
Avenue de Sécheron 15
1202 Geneve
Switzerland
Links
https://www.earlysight.com/
Diseases & Conditions
Sections
EarlySight aims to reduce vision loss by enabling efficient detection and better monitoring of eye diseases. The company develops a high-performance eye imaging instrument in the form of a unique ophthalmic camera, empowering doctors to see the first disease impacts. Its technology allows visualizing the morphology of many cells in the retina that are playing key roles in the disease degenerative process and that were invisible to ophthalmic instruments before. As a result, EarlySight can greatly improve the detection and monitoring of many diseases, such as age-related macular degeneration, glaucoma, and diabetic retinopathy. It will also provide quantitative evidence of treatment efficacy and speed up the development of new therapies.
Founded 2019
Employees 10+
Primary contact
Avenue de Sécheron 15
1202 Geneve
Switzerland
Links
https://www.earlysight.com/
Diseases & Conditions
Sections

Funding 💰

Total $3.4M
Last round 🔗 €2M
May 26, 2021.
Select investors MassChallenge, Verve Ventures, Nina Capital, Venture Kick, Foundation for Technological Innovation (FIT)

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Big market: Blindness and severe vision impairment consecutive to eye diseases affects more than 200 million people worldwide.
  • Solving a problem: Current diagnoses come up too late and treatment is not optimal for many diseases. The reason is the difficulty of assessing the disease state and the treatment effect due to the limitations of the standard imaging instruments. EarlySight has a solution.
  • Science-backed tech: EarlySight's proprietary technology is coming out of the Swiss Federal Institute of Technology Lausanne (EPFL). It allows the system to reach the deepest layer of the retina while creating high contrast. Coupled with advanced optical components, the technology enables recording images of tissue cellular structure in only a few seconds. 🔗
  • It's fast: With EarlySight technology, assessing the retina state of health and monitoring treatment effects can be done non-invasively in only few seconds, without having to wait months for visual acuity changes.

Awards & Recognitions 🏆

  • 2021 Top 100 Swiss Startup Award: 84th place 🔗

Quotes 💬

“
The need for deeper understanding and earlier diagnosis of retinal diseases is only going to increase with the current trends of an aging population. Earlysight has the right ingredients to address this need. We are thrilled to back the Earlysight team and look forward to continuing the journey with them and supporting them in achieving our shared vision.
— Sebastian Anastassiou, Nina Capital 🔗
“
Preliminary results indicate a large window of action between the early onset of the disease and current diagnosis timing, thus confirming the clinical use case. EarlySight is also very relevant for pharmaceutical development, as the lack of objective clinical endpoints has made the development of early treatment difficult. Overall, EarlySight really has the potential to be the next breakthrough technology in retinal imaging, in the same way that OCT was 20 years ago.
— Susanne Schorsch, Investment Manager at Verve Ventures 🔗
Last update: August 22, 2022